BioVie Inc logo

BIVI - BioVie Inc Share Price

$26.06 1.6  6.4%

Last Trade - 02/03/21

Small Cap
Market Cap £244.8m
Enterprise Value £236.3m
Revenue £n/a
Position in Universe 3919th / 6633
Unlock BIVI Revenue
Relative Strength (%)
1m -27.6%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -46.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, BioVieInc revenues was not reported. Net loss applicable tocommon stockholders increased from $14.3M to $49.3M. Highernet loss reflects Selling, general and administrativeincrease from $614K to $2.3M (expense), Research anddevelopment expenses increase of 51% to $1M (expense).Basic Earnings per Share excluding Extraordinary Itemsdecreased from -$3.78 to -$7.97.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


BIVI Revenue Unlock BIVI Revenue

Net Income

BIVI Net Income Unlock BIVI Revenue

Normalised EPS

BIVI Normalised EPS Unlock BIVI Revenue

PE Ratio Range

BIVI PE Ratio Range Unlock BIVI Revenue

Dividend Yield Range

BIVI Dividend Yield Range Unlock BIVI Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BIVI EPS Forecasts Unlock BIVI Revenue
Profile Summary

BioVie Inc clinical-stage company pursuing the discovery, development, and commercialization of drug therapies for liver disease. The Company has developed a new drug candidate, BIV201 (continuous infusion terlipressin) and has completed a mid-stage Phase IIa clinical trial for treating ascites due to advanced liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The Company is developing BIV201, a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH) and alcoholism. The initial target for BIV201 therapy is refractory ascites, a serious complication of liver cirrhosis with an estimated 50% mortality rate within six to 12 months.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated April 10, 2013
Public Since January 14, 2014
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 13,916,164
Free Float (0.0%)
Eligible for
BIVI Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BIVI
Upcoming Events for BIVI
Frequently Asked Questions for BioVie Inc
What is the BioVie Inc share price?

As of 02/03/21, shares in BioVie Inc are trading at $26.06, giving the company a market capitalisation of £244.8m. This share price information is delayed by 15 minutes.

How has the BioVie Inc share price performed this year?

Shares in BioVie Inc are currently trading at $26.06 and the price has moved by 0.654k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BioVie Inc price has moved by 0.511k% over the past year.

What are the analyst and broker recommendations for BioVie Inc?

There are no analysts currently covering BioVie Inc.

When will BioVie Inc next release its financial results?

BioVie Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the BioVie Inc dividend yield?

BioVie Inc does not currently pay a dividend.

Does BioVie Inc pay a dividend?

BioVie Inc does not currently pay a dividend.

When does BioVie Inc next pay dividends?

BioVie Inc does not currently pay a dividend.

How do I buy BioVie Inc shares?

To buy shares in BioVie Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BioVie Inc?

Shares in BioVie Inc are currently trading at $26.06, giving the company a market capitalisation of £244.8m.

Where are BioVie Inc shares listed? Where are BioVie Inc shares listed?

Here are the trading details for BioVie Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: BIVI
What kind of share is BioVie Inc?

Based on an overall assessment of its quality, value and momentum, BioVie Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a BioVie Inc share price forecast 2021?

We were not able to load any forecast data for BioVie Inc.

How can I tell whether the BioVie Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioVie Inc. Over the past six months, the relative strength of its shares against the market has been 11.01%. At the current price of $26.06, shares in BioVie Inc are trading at 50.84% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BioVie Inc PE Ratio?

We were not able to find PE ratio data for BioVie Inc.

Who are the key directors of BioVie Inc?

BioVie Inc's management team is headed by:

Rajah Menon - DRC
Terren Peizer - CEO
Jonathan Adams - PRE
J. Wendy Kim - CFO
Patrick Yeramian - OTH
Penelope Markham - CSO
Richard Berman - DRC
Robert Hariri - DRC
Steven Gorlin - DRC
Sigmund Rogich - DRC
Who are the major shareholders of BioVie Inc?

Here are the top five shareholders of BioVie Inc based on the size of their shareholding:

Acuitas Group Holdings LLC Corporation
Percentage owned: 80.26% (11.2m shares)
Do Cuong Viet Individual Investor
Percentage owned: 0.7% (96.8k shares)
swisspartners Ltd. Investment Advisor
Percentage owned: 0.54% (75.0k shares)
Adams (Jonathan M) Individual Investor
Percentage owned: 0.46% (63.7k shares)
Lang (James Paul) Individual Investor
Percentage owned: 0.18% (25.0k shares)
Similar to BIVI
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.